Stay updated on Niraparib vs Physician's Choice in BRCA+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Niraparib vs Physician's Choice in BRCA+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Niraparib vs Physician's Choice in BRCA+ Breast Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The displayed ClinicalTrials.gov site revision changed from v3.8.0 to v3.8.1, while the study information remained unchanged.
    Difference
    0.0%
    Check dated 2026-11-18T00:50:40.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The clinical trial record for the niraparib-versus-physician’s-choice breast cancer study is displayed, with study design, results, eligibility, and participating locations. It states that the study was terminated due to futility and is no longer recruiting.
    Difference
    100%
    Check dated 2026-11-10T18:42:11.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0, while the study record remains inaccessible behind a 403 error.
    Difference
    0.2%
    Check dated 2026-11-03T19:09:12.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    A site-wide NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the page, and the site revision changes to v3.7.2. The study record itself still displays a 403 error.
    Difference
    1%
    Check dated 2026-10-20T19:26:32.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov study page still displays a 403 Forbidden error. Its footer revision label changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T19:23:21.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    Access to the study record NCT01905592 is blocked by a 403 Forbidden error, removing the study details and locations from the page. Users are presented with a 403 error page instead of the expected study information.
    Difference
    18%
    Check dated 2026-09-22T22:19:20.000Z thumbnail image

Stay in the know with updates to Niraparib vs Physician's Choice in BRCA+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Niraparib vs Physician's Choice in BRCA+ Breast Cancer Clinical Trial page.